Abstract

The Arenaviridae family of segmented RNA viruses contains nearly 70 species with several associated with fatal haemorrhagic fevers, including Lassa, Lujo and Junin viruses. Lymphocytic choriomeningitis arenavirus (LCMV) is associated with fatal neurologic disease in humans and additionally represents a tractable model for studying arenavirus biology. Within cultured cells, a high proportion of LCMV spread is between directly neighbouring cells, suggesting infectivity may pass through intercellular connections, bypassing the canonical extracellular route involving egress from the plasma membrane. Consistent with this, we visualized abundant actin- and tubulin-rich connections conjoining LCMV-infected and uninfected cells within cultures, resembling tunnelling nanotubes (TNTs). Within these TNT-like connections, confocal and STED microscopy identified puncta containing the major structural components of LCMV virions alongside genomic RNA, consistent with intercellular transit of assembled virions or ribonucleoprotein genome segments. Blocking the extracellular route of infection by adding potent LCMV neutralising antibody M28 to supernatants during infection revealed around 50% of LCMV transmission was via intercellular connections. These results show arenaviruses transmission is more complex than previously thought involving both extracellular and intercellular routes.

Details

Title
Lymphocytic choriomeningitis arenavirus utilises intercellular connections for cell to cell spread
Author
Byford, Owen 1 ; Shaw, Amelia B. 1 ; Tse, Hiu Nam 1 ; Moon-Walker, Alex 2 ; Saphire, Erica Ollmann 3 ; Whelan, Sean P. J. 4 ; Stacey, Martin 5 ; Hewson, Roger 6 ; Fontana, Juan 1 ; Barr, John N. 1 

 University of Leeds, School of Molecular and Cellular Biology, Faculty of Biological Sciences, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403); University of Leeds, Astbury Centre for Structural Molecular Biology, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403) 
 Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162); Washington University in St. Louis, Department of Molecular Microbiology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0004 1936 9350); Harvard Medical School, Program in Virology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Merck Research Laboratories, Merck & Co, Cambridge, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793) 
 Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162) 
 Washington University in St. Louis, Department of Molecular Microbiology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0004 1936 9350) 
 University of Leeds, School of Molecular and Cellular Biology, Faculty of Biological Sciences, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403) 
 Virology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, UK (GRID:grid.271308.f) (ISNI:0000 0004 5909 016X) 
Pages
28961
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3132021643
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.